摘要
本文通过介绍日本厚生劳动省对化学药品先发品的确定路径及管理模式,为我国拟选择日本上市先发品作为参比制剂的仿制药研发企业提供参考,同时为监管机构对我国化学仿制药参比制剂的确定提供参考。
Based on the introduction to the determination path and management model of chemical initial products in the Ministry of Health,Labour and Welfare of Japan,this article provides reference for generic drug research and development enterprises in China that intend to select Japanese listed initial products as reference preparations and provides reference for regulatory agencies to determine the reference preparations of chemical generic drugs in China.
作者
刘意林
宁黎丽
李芳
安娜
哈莉莉
郭志鑫
LIU Yi-lin;NING Li-li;LI Fang;AN Na;HA Li-li;GUO Zhi-xin(Center for Drug Evaluation,National Medical Products Administration,Beijing 100022,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2024年第10期984-987,共4页
Chinese Journal of New Drugs
关键词
日本
先发品
确定路径
管理模式
Japan
initial products
path determination
management model